Dr. Rana McKay

And I think the next generation of hormonal agents, we've got CYP11 inhibitors that now not, you know, the abiraterone is a CYP17 inhibitor, blocks a little bit lower down in the adrenal hormonal axis. You know, MK5684 is a CYP11 inhibitor that blocks even higher up. preventing cholesterol from entering into the hormone production pathway.

And I think the next generation of hormonal agents, we've got CYP11 inhibitors that now not, you know, the abiraterone is a CYP17 inhibitor, blocks a little bit lower down in the adrenal hormonal axis. You know, MK5684 is a CYP11 inhibitor that blocks even higher up. preventing cholesterol from entering into the hormone production pathway.

And it can be associated with adrenal insufficiency type symptoms. So mineralocorticoid deficiency in addition to glucocorticoid deficiency. And so that is coming down the pike. We've seen some pretty promising data. There's also AR degraders, AR protags. There are different kinds of ways to further kind of block the androgen access.

And it can be associated with adrenal insufficiency type symptoms. So mineralocorticoid deficiency in addition to glucocorticoid deficiency. And so that is coming down the pike. We've seen some pretty promising data. There's also AR degraders, AR protags. There are different kinds of ways to further kind of block the androgen access.

And it can be associated with adrenal insufficiency type symptoms. So mineralocorticoid deficiency in addition to glucocorticoid deficiency. And so that is coming down the pike. We've seen some pretty promising data. There's also AR degraders, AR protags. There are different kinds of ways to further kind of block the androgen access.

So I think there's a lot of cool stuff coming down the pike that hopefully will enhance patients' survival and not be associated with too much toxicity.

So I think there's a lot of cool stuff coming down the pike that hopefully will enhance patients' survival and not be associated with too much toxicity.

So I think there's a lot of cool stuff coming down the pike that hopefully will enhance patients' survival and not be associated with too much toxicity.

Thank you, Aditya.

Thank you, Aditya.

Thank you, Aditya.